ALL: Combining paediatric-type therapy with minimal residual disease
5 Dec 2016
ALL: Combining paediatric-type therapy with minimal residual disease
ASH 2016: AML, CLL and leukaemogenesis latest
Venetoclax plus cytarabine in elderly AML patients
Remissions following anti-CD22 CAR therapy in children with relapsed ALL
Mutational drivers of thyroid cancer
Gold nanoparticles and cancer treatment
Towards delivering truly personalised therapy for oesophageal cancer
Improving the evidence base for symptom control
Highlights of the SIOG posterwalk
Advancements in the field of geriatric oncology
Closing poll on CDK inhibition in advanced breast cancer with failing antiestrogens
TAT 2017 congress provides the latest in Phase I targeted therapies